Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma

Mucosal Melanoma Clinical Trial

Official title:

A Monocentric, Single-arm, Open, Phase II Clinical Study on the Efficacy and Safety of Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Localized Mucosal Melanoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04180995
• Other study ID #: JS001-ISS-132
• Status: Recruiting
• Phase: Phase 2
• Start date: August 6, 2019
• Est. completion date: December 30, 2022

Study information

• Verified date: January 2022
• Source: Beijing Cancer Hospital
• Contact: Chuanliang Cui, Dr
• Phone: '+8613691489319
• Email: 1008ccl[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is one monocentric, single-arm, open, phase Ⅱ clinical study to evaluate the safety and efficacy of Toripalimab monoclonal injection (Tuo Yi) combined with axitinib tablet (Inlyta®) as neoadjuvant therapy for localized mucosal melanoma.

Primary objective: To evaluate pathological response (pCR+pPR) rate of Toripalimab combined with axitinib as neoadjuvant therapy for localized mucosal melanoma.

The subjects will receive Toripalimab and Axitinib combined therapy after enrollment, and receive operation 2 weeks after the last dose of Axitinib. Toripalimab will be given for a total of 4 cycles (8 weeks), whereas Axitinib will be given for a total of 8 weeks.The subjects can receive Toripalimab for up to one year after the operation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 30, 2022
• Est. primary completion date: July 6, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Being voluntary to sign the informed consent form, with good compliance and willingness to cooperate with follow-up;

2. Age of 18-75 years, male or female;

3. Histopathologically diagnosed mucosal melanoma;

4. ECOG PS score 0 or 1;

5. Being considered to be able to be completely resected after multidisciplinary (including surgeon, oncologist and radiologist) discussion, and systemic staging examination improved prior to enrollment (need to include cranial enhanced CT/MRI, bone scan, thoracic, abdominal and pelvic enhanced CT/MRI (enhanced MRI of head and neck, gynecological examination additionally needed for female genital melanoma, colonoscopy additionally needed for rectal melanoma), B mode ultrasonography of superficial lymph node, or systemic PET-CT) demonstrated no regional or distant metastasis;

6. No contraindications for the treatment, including normal peripheral hemogram, basically normal hepatic and renal function as well as ECG:

• Peripheral hemogram: white blood cell (WBC) =3.5×109/L, neutrophil (ANC) =1.5×109/L, platelet (PLT) =100×109/L, hemoglobin (Hgb) =90 g/L;

• Liver function: alanine aminotransferase (ALT) =1.5×ULN, aspartate aminotransferase (AST) =1.5×ULN, and total bilirubin (TBil) =1.5×ULN;

• Renal function: blood urea nitrogen = ULN, creatinine = ULN;

7. Use of highly-effective contraceptive methods during the whole study for men of reproduction ability or women of pregnant possibility (e.g. oral contraceptives, intrauterine contraceptive device, abstinence of sexual intercourse or barrier contraception in combination with spermatocide), and continuation of contraception for 12 months after the end of study treatment.

Exclusion Criteria:

1. Previously treated with anti-PD-1, anti-PD-L1, anti-PD-L2, or antiangiogenic drugs;

2. Known allergy to Toripalimab or Axitinib or excipient of the study drug;

3. Patients with ocular melanoma or melanoma with unknown primary foci;

4. Pregnant and breastfeeding women;

5. Abnormal coagulation function [activated partial thromboplastin time (APTT)> 43 s, or international normalized ratio (INR) > 1.5×ULN], or hemorrhagic tendency or hemorrhagic event occurred within two months prior to enrollment (e.g., gastrointestinal hemorrhage, hemorrhagic gastric ulcer, etc.), or receiving thrombolytic or anticoagulation therapy;

6. Currently having serious and uncontrolled acute infection, or suppurative infection, chronic infection, or prolonged wound healing;

7. Having serious heart disease, including congestive heart failure, uncontrollable high-risk arrhythmia, unstable angina pectoris, myocardial infarction, severe valvular heart disease and refractory hypertension;

8. Having neurological, mental disease or psychiatric disorder that can not be easily controlled, poor compliance, inability to cooperate and narrate therapeutic response;

9. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;

10. Concomitantly other Malignancies;

11. Concomitant participation in other clinical trials;

12. Positive HIV antibody, or positive HCV antibody/HCV-RNA, or positive HBsAg or HBcAb whilst HBV DNA copy >2000 IU/ml;

13. Active autoimmune diseases requiring systemic treatment in the past two years (e.g., use of disease-regulating drug, corticosteroid or immunosuppressant), relevant replacement therapy is allowed (e.g., thyroxine, insulin or physiological corticosteroid replacement therapy for renal or pituitary insufficiency);

14. Vaccination of live vaccine within 4 weeks prior to the start of study;

15. Other severe, acute or chronic medical diseases or abnormalities in laboratory examination possibly increasing the relevant risk in study participation or possibly interfering the interpretation of study results as judged by the investigators.

Related Conditions & MeSH terms

• Melanoma
• Mucosal Melanoma

Intervention

Drug:
• TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)
TORIPALIMAB INJECTION(JS001 ) combined with chemotherapy, 3mg/kg, Q2W,up to 1 years of treatment.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	PD-L1 expression	Correlation between predictive biomarkers and efficacy, including PD-L1 expression.	2 years
Other	CD3 and CD8 gene mutation	Correlation between predictive biomarkers and efficacy, including CD3 and CD8, gene mutation status, etc.	2 years
Primary	Pathological response (pCR+pPR) rate: defined as the percentage of subjects without alive tumor cells and alive tumor cells in postoperative resected specimens 10% - 50% in the resected specimen post operation.	To evaluate pathological response (pCR+pPR) rate of Toripalimab combined with axitinib as neoadjuvant therapy for localized mucosal melanoma.	Approximately 8 weeks
Secondary	RFS (recurrence-free survival) per RECIST1.1 as Assessed by investigator	To evaluate recurrence-free survival (RFS) of Toripalimab combined with axitinib as neoadjuvant therapy for localized mucosal melanoma.	Approximately 1 years
Secondary	OS (overall survival)	OS at 1 or 2 years.	Approximately 2 years
Secondary	Incidence of AEs/SAEs	Adverse events (AEs) ; serious adverse events (SAEs); abnormal value of Lab test according to NCI-CTCAE V5.0	Approximately 2 years
Secondary	Pathological complete response (pCR) rate: defined as the percentage of subjects without alive tumor cells in the resected specimen post operation.	To evaluate pathological complete response (pCR) rate of Toripalimab combined with axitinib as neoadjuvant therapy for localized mucosal melanoma.	Approximately 8 weeks